Study On Clinical And Biological Features Of Peripheral T-cell Lymphomas

OBJECTIVE To summarize clinical features and treatment outcomes ofperipheral T-cell lymphoma,non specified.METHODS Records of 78 patients with PTCL-US treated from Jan 1994 toDec. 2004 in cancer hospital of Chinese medical science institute were retrospectivelyanalyzed.All patients were classified according to REAL or WHO criteria.RESULTS Median age of the whole group was 39 years (ranged 7-75 years);of78 petients,20 were female, 58 were male; 34(43. 7%) were treated withchemoradiotherapy, 43 (55%) were treated with chemotherapy alone; 13(55.8%)patients treated with autologous blood stem cell transplantation after achieveing CRor PR.With a median follow up of months,the 5-year survival rates of the whole groupwas 41.4%,the 5-year progressive-free survival rate was 33.8%;The 5-year survivalrates of CR,PR,PD/SD group were 65.1%,21.9% and 0%, the 5-year OS forpatients treated with first-line APBSCT was 61.5% while 52.3% for those treated withconventional dose therapy alone(P=0.894)。.International prognostic index andprognostic index for peripheral T-cell lymphoma were significant factor for predictingoverall survival .The 5-year survival rate of low risk, low-intermediaterisk ,intermediate high risk and high risk group were 67.9%,35.0%,22.2%,9.1%。CONCLUSION PTCL-US are rare lymphomas Present treatment modilitiesfor T-cell NHL patients,especially the high risk patients ,can't achieve satisfactoryoutcomes.New treatment modality for these patients need to be explored. Objective:Analyze the expression status of NF-κB and PDGFR-αin peripheralT-cell lymphomas(PTCLs) tissue,study the relationship with clinicalfactors, investigate the possibilities of using NF-κB inhibitors and tysorine kinaseinhibitors to treat PTCL.Material and method:Collect the formalin-fixed,paraffin-bedded tissues of 48PTCL patients treated in cancer hospital of CAMS from 1994 to 2004.Examin theNF-κB-p65 and PDGFR-αexpression with immunohistochemical method.UsingSPSS13.0 statistical soft ware to evaluate the association with clinical parameters andtreatment outcome.Results: 89.6% patients expression NF-κB3-p65, which locating on the nucleu, 23cases were high expression(2+or 3+), for patients with high expression, 16 casesexhibited refractory to treatment or developed metastases later, while those patientshave non or weak expression responded well, there are different significently(p=0.02),NF-κB-p65 expression have no relationship with other clinical factors such asextranodal involvement and stage; PDGFR-αwere expressioned on 91.7%patients,half were high expression(2+,3+),There were no relationship betweenexpression of PDGFR-αand other clinical parameters; On multivarinate anlysis,NF-κB-p65 overexpression were the indepdent prognostic factor of 5 year PFS.Conclusion:Most PTCLs have NF-κB-p65 and PDGFR-αexpression.Aftertreatment,most patients with high NF-κB-p65 expression exhibited refractory totreatment or relapsed later, NF-κB inhibitor and tyrosine kinase inhibitors targetingPDGFR-αshould be studied in this kind of disease in the future.